Quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines - Scientific guideline
HumanScientific guidelinesVaccines
This document provides recommendations on the quality, non-clinical and clinical studies that should be performed in order to obtain marketing authorisation of a live recombinant viral vectored vaccine intended for use in the prophylaxis of infectious disease in humans. Plasmid DNA vaccines, recombinant protein vaccines and vaccines against non-infectious indications, i.e. 'immunotherapeutic' medicinal products, are not within the scope of this guideline. Vaccines based upon bacterial vectors such as salmonella and Bacillus Calmette-Guérin are also not within the scope of this guideline, although many of the principles that apply here could also apply to these vaccines.
Keywords: Live recombinant viral vectored vaccine, heterologous antigen
Current effective version
Related content
- Biologicals: active substance
- Multidisciplinary: vaccines
- Directive 2001/83
- Regulation (EC) No 726/2004
Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products- DNA vaccines
- Environmental risk assessments for medicinal products containing, or consisting of, genetically modified organisms (GMOs) (Module 1.6.2)
- Quality, preclinical and clinical aspects of gene transfer medicinal products